Tuccinardi D, et al. - In this 6-month-long, randomized, placebo-controlled, double-blind clinical trial, authors assessed the impact of lorcaserin administration on body weight and cardiometabolic risk among 48 obese candidates. They observed a reduction in fat mass, the Fatty Liver Index, and energy intake with no impact on energy expenditure or lean mass with lorcaserin treatment. They also noticed a decline in total low-density lipoprotein (LDL) and small LDL particles. An increase in total high-density lipoprotein (HDL) and a significant decrease in heart rate with lorcaserin administration was also reported. They observed no mRNA expression of the 5-HT2C receptor in peripheral organs. Overall, they found improvement in cardiometabolic health due to lorcaserin treatment for 6 months, chiefly working through the brain in obese cases.